BioSpace News Archive

SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal disease, today announces a key advancement in its Phase I/II clinical trial (PRODYGY, NCT05748873) for SPVN06, the Company’s lead gene-agnostic investigational gene therapy for the treatment of retinitis pigmentosa (RP).

Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2023 results.

MiNA Therapeutics Limited announced today that it will present new pre-clinical data for its lead RNA activation program targeting fetal hemoglobin (HbF) at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference in Banff, Alberta, Canada.

Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study.

TFF Pharmaceuticals, Inc. today announced that the Company will present data from the Phase 2 trial of Voriconazole Inhalation Powder (TFF VORI) for the treatment of invasive pulmonary aspergillosis at the upcoming Advances Against Aspergillosis & Mucormycosis (AAAM) Conference, which will be held from January 25-27, 2024, in Milan, Italy.

ZyVersa Therapeutics, Inc is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 have published a scientific paper in the peer-reviewed journal, Alzheimer’s & Dementia: Translational Research & Clinical Interventions.

Annovis Bio, Inc. has announced a postponement in the Phase III study data release for buntanetap in Parkinson’s Disease.

Onward Therapeutics SA announced that the phase 1 clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress.

IMU Biosciences announces the close of a £11.5 million Series A financing round.

The MEDITWIN consortium was announced on December 11, 2023, in the presence of French President Emmanuel Macron.